Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
about
Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in childrenCombination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenFormoterol versus short-acting beta-agonists as relief medication for adults and children with asthmaAddition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in childrenCombination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and childrenCombination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and childrenAdd-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhalerA systematic review with attempted network meta-analysis of asthma therapy recommended for five to eighteen year olds in GINA steps three and fourThe Saudi Initiative for Asthma.Achieving control of asthma in preschoolers.Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol.Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthmaPediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.Pharmacogenomics of long-acting β2-agonists.Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network.Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.Long-acting beta-agonists and the risk of intensive care unit admission in children.beta-Adrenergic receptor polymorphisms and response to salmeterol.Asthma control in adolescents: role of leukotriene inhibitors.An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids.Update in paediatric asthma management: where is evidence challenging current practice?Do genetic polymorphisms alter patient response to inhaled bronchodilators?The effects of asthma medications on reactive oxygen species production in human monocytes.Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective.Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma.Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma.Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.Use and safety of long-acting β2-agonists for pediatric asthma
P2860
Q24187686-631D524C-6F01-4EF2-8FB1-F7A6ED7040DEQ24201774-6E01674F-F193-4948-8663-71FB69C9198AQ24235303-199E9407-A442-44D5-8CFE-B79AB2EFAFACQ24235496-AB72AA83-CEF9-4956-B88C-AE20E2048723Q24239922-DD8DEE67-F32D-4598-A930-E3DF066F4C25Q24241025-B3844F14-74AC-4D3E-BCB5-DA08587C1532Q24241556-8D0E96A8-2A65-4857-B85A-D2D01358CB66Q28596628-918721F1-FBBC-4F70-9A50-7FAEC9FBFAAEQ30536662-0A686A25-7224-4F2E-BE6A-A930F09B7FB5Q33568644-3D242240-5BF3-4E53-8AD6-E1C6D5A64FF8Q33701635-90773E08-A293-4CD1-AE28-8A739827CA74Q33715425-B626BA73-1D9A-4B90-B58A-B419E0921F50Q34016209-CCA33A65-D2E1-46ED-A7CF-800C05F2FE57Q34625206-59CA7AD3-3C4F-4D5D-988F-22AB21D189ECQ35734012-28B8AB0E-6712-4C2A-82E0-CFF92954A82DQ36671746-BBBAFAA0-0023-47C5-AAD1-EB5610F5E359Q36892408-16E3D8B5-E924-4FBE-8E7A-5077DFCC6B74Q36912259-245E4FBE-A50A-4382-84A7-02E76604F584Q37144386-512E760A-C7EA-4920-B743-945555E1CE6AQ37561894-C6E1BB9A-B5C7-47EB-A7C6-5B81584BC964Q37735203-2FC7C951-1C4C-473E-9E25-6CF05CDFFB93Q37862373-C8661A5A-74F4-4E89-BAD2-F4843F743225Q38237766-5018D94D-DF7C-4EC1-83AC-46D733236A62Q38697563-B6BDDDD7-1F1F-4E3C-9291-34AD6F0E0E60Q38951196-64369C66-0997-4A65-A1E2-71560F7BBD79Q39374605-AC1FA974-8D38-4B6D-A8AB-EF3293BB5A99Q42973500-C7D02ABB-9909-45ED-91A2-17EDB3FF10B9Q53229520-5778DDDA-B19F-492A-B4E3-8164ED6B478FQ55414847-98CEEAD3-0AF4-449D-AD04-2239576FFB5AQ57821604-689583C2-D3A6-4D8C-9218-18E297CD593D
P2860
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@ast
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@en
type
label
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@ast
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@en
prefLabel
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@ast
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@en
P356
P1476
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
@en
P304
P356
10.1002/PPUL.10381
P577
2003-11-01T00:00:00Z